SINTX Technologies Secures Patent Allowance for Wide-Ranging Silicon Nitride Biomaterial Applications
SINTX Technologies (NASDAQ: SINT) has received a Notice of Allowance from the USPTO for patent application no. 17/237,687, titled 'Methods of Silicon Nitride Laser Cladding.' The patent covers a method for laser bonding bioactive silicon nitride to various biomedical implant substrates, including titanium, alumina, zirconia, and advanced polymers.
This technology complements their recently granted U.S. Patent (US 12162807) and enhances traditional implant materials with silicon nitride's osseointegration and bacterial resistance properties. As the only FDA-registered producer of implantable silicon nitride, SINTX has developed the material in both monolithic and particulate forms for various applications.
The company's intellectual property portfolio now includes 17 issued U.S. patents and 84 pending patent applications worldwide.
SINTX Technologies (NASDAQ: SINT) ha ricevuto un Avviso di Concessione dall'USPTO per la domanda di brevetto n. 17/237,687, intitolata 'Metodi di Ricopertura Laser in Nitruro di Silicio.' Il brevetto copre un metodo per il legame laser di nitruro di silicio bioattivo a vari substrati impiantabili biomedici, tra cui titanio, allumina, zirconia e polimeri avanzati.
Questa tecnologia completa il loro recente brevetto statunitense concesso (US 12162807) e migliora i materiali impiantabili tradizionali grazie alle proprietà di osteointegrazione e resistenza batterica del nitruro di silicio. Essendo l'unico produttore di nitruro di silicio impiantabile registrato dalla FDA, SINTX ha sviluppato il materiale in forme sia monolitiche che particellari per varie applicazioni.
Il portafoglio di proprietà intellettuale dell'azienda include ora 17 brevetti statunitensi concessi e 84 domande di brevetto pendenti in tutto il mondo.
SINTX Technologies (NASDAQ: SINT) ha recibido un Aviso de Concesión de la USPTO para la solicitud de patente no. 17/237,687, titulada 'Métodos de Recubrimiento Láser de Nitruro de Silicio.' La patente cubre un método para la unión láser de nitruro de silicio bioactivo a varios sustratos de implantes biomédicos, incluyendo titanio, alúmina, zirconia y polímeros avanzados.
Esta tecnología complementa su reciente patente concedida en EE.UU. (US 12162807) y mejora los materiales de implantes tradicionales con las propiedades de osteointegración y resistencia bacteriana del nitruro de silicio. Siendo el único productor de nitruro de silicio implantable registrado por la FDA, SINTX ha desarrollado el material en formas tanto monolíticas como particuladas para diversas aplicaciones.
El portafolio de propiedad intelectual de la empresa ahora incluye 17 patentes emitidas en EE.UU. y 84 solicitudes de patente pendientes en todo el mundo.
SINTX Technologies (NASDAQ: SINT)는 '실리콘 나이트라이드 레이저 클래딩 방법'이라는 제목의 특허 신청 번호 17/237,687에 대해 USPTO로부터 허가 통지를 받았습니다. 이 특허는 생체 활성 실리콘 나이트라이드를 타이타늄, 알루미나, 지르코니아 및 고급 폴리머를 포함한 다양한 생의학 임플란트 기판에 레이저 결합하는 방법을 다룹니다.
이 기술은 최근에 부여된 미국 특허(US 12162807)를 보완하며 실리콘 나이트라이드의 골유착 및 박테리아 저항성 특성으로 전통적인 임플란트 재료를 향상시킵니다. FDA에 등록된 유일한 이식 가능한 실리콘 나이트라이드 생산업체인 SINTX는 다양한 응용 분야를 위한 단일체 및 입자 형태로 재료를 개발했습니다.
회사의 지적 재산 포트폴리오는 이제 17개의 미국 특허와 전 세계 84개의 특허 신청을 포함하고 있습니다.
SINTX Technologies (NASDAQ: SINT) a reçu un Avis de Concession de l'USPTO pour la demande de brevet n° 17/237,687, intitulée 'Méthodes de Revêtement Laser en Nitrure de Silicium.' Le brevet concerne une méthode de fusion laser du nitrure de silicium bioactif avec divers substrats d'implants biomédicaux, y compris le titane, l'alumine, la zircone et des polymères avancés.
Cette technologie complète leur brevet américain récemment accordé (US 12162807) et améliore les matériaux d'implant traditionnels grâce aux propriétés d'ostéointégration et de résistance bactérienne du nitrure de silicium. En tant que seul producteur de nitrure de silicium implantable enregistré par la FDA, SINTX a développé le matériau à la fois sous forme monolithique et particulaire pour diverses applications.
Le portefeuille de propriété intellectuelle de l'entreprise comprend désormais 17 brevets américains délivrés et 84 demandes de brevet en attente dans le monde entier.
SINTX Technologies (NASDAQ: SINT) hat eine Mitteilung über die Genehmigung vom USPTO für die Patentanmeldung Nr. 17/237,687, betitelt 'Methoden zur Laserbeschichtung von Siliziumnitrid', erhalten. Das Patent beschreibt eine Methode zur Laserverklebung von bioaktivem Siliziumnitrid mit verschiedenen biomedizinischen Implantatunterlagen, einschließlich Titan, Al2O3, Zirkonia und hochentwickelten Polymeren.
Diese Technologie ergänzt ihr kürzlich erteiltes US-Patent (US 12162807) und verbessert traditionelle Implantatmaterialien mit den Eigenschaften der Osseointegration und der bakteriellen Resistenz von Siliziumnitrid. Als einziger von der FDA registrierter Hersteller von implantierbarem Siliziumnitrid hat SINTX das Material sowohl in monolithischer als auch in partikulärer Form für verschiedene Anwendungen entwickelt.
Das geistige Eigentum des Unternehmens umfasst jetzt 17 erteilte US-Patente und 84 ausstehende Patentanmeldungen weltweit.
- Patent allowance strengthens SINTX's intellectual property portfolio and market position
- Technology enables enhancement of existing medical devices with superior properties
- Exclusive FDA-registered producer status for implantable silicon nitride
- Diverse application potential across medical and technical markets
- None.
Insights
The patent allowance for silicon nitride laser cladding technology represents a meaningful technical advancement in biomaterial applications. The ability to bond bioactive silicon nitride to various implant substrates could significantly enhance the performance of medical implants by combining silicon nitride's osseointegration and antibacterial properties with traditional materials' structural benefits.
The technology's versatility in coating different substrates, including titanium and advanced polymers, opens new possibilities for improving existing implant designs. Being the sole FDA-registered producer of implantable silicon nitride gives SINTX a unique market position. However, the
This patent allowance strengthens SINTX's IP portfolio in a strategically important area. With 17 issued U.S. patents and 84 pending applications globally, the company is building substantial barriers to entry in silicon nitride applications. The laser cladding method is particularly valuable as it enables both new device development and potential retrofitting of existing implants - creating dual market opportunities.
The technology complements their recent US 12162807 patent, creating a more comprehensive IP protection around their core technology. However, translating these patents into commercial success will require significant investment in manufacturing scale-up and market development, which may be challenging given their current financial position.
Salt Lake City, Utah, Dec. 17, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics company specializing in developing and commercializing materials for medical and technical applications, has achieved a significant milestone. The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for SINTX’s patent application no. 17/237,687, titled “Methods of Silicon Nitride Laser Cladding.” This milestone underscores SINTX’s leadership in biomaterial innovation and reinforces its robust intellectual property portfolio.
The patent, expected to be issued soon, protects a revolutionary method for laser bonding bioactive silicon nitride to various biomedical implant substrates, including titanium, alumina, zirconia, and advanced polymers like PEKK. This breakthrough technology enhances the biological performance of these substrates by imparting silicon nitride’s superior osseointegration and bacterial resistance properties.
“This patent allowance demonstrates SINTX’s relentless pursuit of innovation,” said Eric K. Olson, President and CEO of SINTX. “By pushing the boundaries of biomaterial science, we’re transforming medical devices with cutting-edge solutions that deliver greater value to patients and healthcare providers. This achievement also reinforces our leadership in the development of advanced ceramics and demonstrates our commitment to improving outcomes in medical and technical applications.”
The technology complements a recently granted U.S. Patent (US 12162807), expanding SINTX’s capabilities to enhance traditional implantable device materials. These advancements not only open new opportunities in the biomedical field but also offer innovative pathways for upgrading existing devices with silicon nitride’s unmatched properties. Additionally, the coating method enables the refinishing of implants, enhancing their functionality and extending their usability—a significant advantage in today’s medical device market.
SINTX remains the only FDA-registered producer of implantable silicon nitride. Alongside its monolithic ceramic implants, the Company has developed silicon nitride in particulate form for use in resins, composites and coatings. These innovations support SINTX’s strategy to broaden the applications of its technology across diverse markets.
With this allowance, SINTX continues to build its extensive intellectual property portfolio, which now includes 17 issued U.S. patents and 84 pending patent applications worldwide. These patents solidify SINTX’s position as a global leader in advanced ceramics and biomaterial innovation.
About SINTX Technologies, Inc.
SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. The Company has manufacturing and R&D facilities in Utah and Maryland. For more information on SINTX Technologies or its materials platform, visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding advancing the development of advanced ceramic for biomaterial applications, opening new opportunities in the biomedical field, offering innovative pathways for upgrading existing devices with silicon nitride’s unmatched properties, and the refinishing of implants, enhancing their functionality and extending their usability.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, difficulty in implementing technological innovations, unanticipated expenses and challenges resulting from introducing new technologies and products, and customer acceptance of these innovations.
A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.
Business and Media Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com
FAQ
What is the significance of SINTX's new patent allowance for silicon nitride laser cladding?
How many patents does SINTX Technologies (SINT) currently hold?
What materials can SINTX's new silicon nitride coating technology be applied to?
Is SINTX (SINT) the only FDA-registered producer of implantable silicon nitride?
What forms of silicon nitride does SINTX (SINT) produce?
